急性肾损伤生物标志物对个体化患者护理的影响
本文综述了急性肾损伤(AKI)生物标志物在个体化患者护理中的作用。传统功能标志物(血肌酐、尿量)的密切监测与改善患者结局相关;生化损伤标志物在临床试验中既用于评估肾损伤,也作为启动治疗干预的触发因素。文章基于作者临床经验,讨论了生物标志物临床实施中的证据优势与局限性。
要点
- 密切监测血肌酐和尿量等传统标志物与改善患者结局相关
- 整合风险因素(电子健康记录监测)和肾储备检测可指导护理集束化实施
- 生化损伤标志物在临床试验中作为肾损伤measures和启动治疗的触发因素
核心结论
- 传统功能标志物密切监测与改善患者结局相关
- 整合风险因素和肾储备检测可优化护理集束化实施
- 生化损伤标志物在临床试验中用于评估肾损伤和触发治疗
研究设计与样本
- 文献综述,基于作者集体临床经验和意见
主要发现
- 密切监测血肌酐和尿量等广泛可用标志物与改善患者结局强相关
- 整合风险因素和肾储备检测可指导护理集束化实施和目标
- 生化损伤标志物在临床试验中用作肾损伤measures和治疗触发因素
临床怎么用
- 整合传统标志物、风险因素和肾储备检测指导护理集束化实施
- 医院实时生物标志物测量需多学科方法实施
局限性
- 基于作者集体临床经验和意见,非系统评价
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute kidney injury (AKI) remains a common clinical syndrome associated with increased morbidity and mortality. In the last several years there have been several advances in the identification of patients at increased risk for AKI through the use of traditional and newer functional and damage biomarkers of AKI. This article will specifically focus on the impact of biomarkers of AKI on individual patient care, focusing predominantly on the markers with the most expansive breadth of study in patients and reported literature evidence. Several studies have demonstrated that close monitoring of widely available biomarkers such as serum creatinine and urine output is strongly associated with improved patient outcomes. An integrated approach to these biomarkers used in context with patient risk factors (identifiable using electronic health record monitoring) and with tests of renal reserve may guide implementation and targeting of care bundles to optimize patient care. Besides traditional functional markers, biochemical injury biomarkers have been increasingly utilized in clinical trials both as a measure of kidney injury as well as a trigger to initiate other treatment options (e.g. care bundles and novel therapies). As the novel measures are becoming globally available, the clinical implementation of hospital-based real-time biomarker measurements involves a multidisciplinary approach. This literature review discusses the data evidence supporting both the strengths and limitations in the clinical implementation of biomarkers based on the authors' collective clinical experiences and opinions.
引用
- Koyner JL, Zarbock A, Basu RK, et al. The impact of biomarkers of acute kidney injury on individual patient care. Nephrol Dial Transplant. 2020. PMID: 31725154. doi:10.1093/ndt/gfz188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。